Information Provided By: 
Fly News Breaks for October 29, 2015
ICPT
Oct 29, 2015 | 08:37 EDT
Morgan Stanley lowered Intercept's price target to $110 following the recently failed Japanese NASH trial. Analyst Andrew Berens has increased that OCA will demonstrate a DIRECT fibrosis benefit, resulting in increased regulatory risk and lowering the potential commercial value. Berens rates Intercept an Underweight rating.
News For ICPT From the Last 2 Days
There are no results for your query ICPT
